SEARCH:
Print

Pipeline

VACCINES IN CLINICAL DEVELOPMENT
PRODUCT INDICATION DEVELOPMENT PHASE COMMERCIAL RIGHTS
    1 2 3 4  
INFECTIOUS DISEASES
IMVAMUNE liquid-frozen * Smallpox . . . . Bavarian Nordic
IMVAMUNE freeze-dried Smallpox . . . . Bavarian Nordic
MVA-BN Filo monovalent ** Ebola . . . . Janssen
MVA-BN Filo multivalent Ebola/Marburg . . . . Janssen
MVA-BN RSV RSV . . . . Bavarian Nordic
CANCER IMMUNOTHERAPY
PROSTVAC combinations *** Prostate cancer . . . . Bristol-Myers Squibb
CV301 + anti-PD-1 Lung cancer . . . . Bavarian Nordic
MVA-BN Brachyury Solid tumors . . . . Bavarian Nordic
* Approved in the European Union under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Phase 3 registration studies are ongoing in the United States.
** Multiple Janssen-sponsored Phase 1, 2 and 3 clinical studies ongoing.
*** Multiple NCI-sponsored Phase 2 clinical studies ongoing.
PRECLINICAL COLLABORATIONS
INFECTIOUS DISEASES
MVA-BN HPV + AdVac Chronic HPV infection Preclinical development Janssen
MVA-BN HBV + AdVac Hepatitis B Preclinical development Janssen
MVA-BN HIV + AdVac HIV-1 Preclinical development Janssen
CANCER IMMUNOTHERAPY
CV301 + atezolizumab Bladder cancer Preclinical development Bavarian Nordic